Estimation of the Absolute Bioavailability of Rivastigmine in Patients with Mild to Moderate Dementia of the Alzheimer???s Type
- 1 January 2002
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 41 (3) , 225-234
- https://doi.org/10.2165/00003088-200241030-00006
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's diseaseActa Neurologica Scandinavica, 2009
- Ongoing trials in Alzheimer’s diseaseExpert Opinion on Investigational Drugs, 2000
- Establishing the Maximum Tolerated Dose of Lesopitron in Patients With Generalized Anxiety DisorderJournal of Clinical Psychopharmacology, 1996
- Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's diseaseLife Sciences, 1996
- A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesteraseLife Sciences, 1994
- Multiple Dose Pharmacokinetics, Safety, and Tolerance of Velnacrine (HP 029) in Healthy Elderly Subjects: A Potential Therapeutic Agent for Alzheimer's DiseaseThe Journal of Clinical Pharmacology, 1990
- Clinical Safety, Tolerance, and Plasma Levels of the Oral Anticholinesterase 1,2,3,4-Tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's Disease: Preliminary FindingsThe Journal of Clinical Pharmacology, 1990
- Alzheimer's Disease: A Disorder of Cortical Cholinergic InnervationScience, 1983
- The Cholinergic Hypothesis of Geriatric Memory DysfunctionScience, 1982
- Differential Sensitivity to the Effects of Psychotropic Drugs: Psychotics vs Normals; Asian vs Western PopulationsPsychiatry and Clinical Neurosciences, 1981